Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Calidi Biotherapeutics Inc. (CLDI) operate in?
Calidi Biotherapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Calidi Biotherapeutics Inc. (CLDI) current stock price?
As of the latest data, Calidi Biotherapeutics Inc. stock price is $1.39, with a previous close of $1.35. Calidi Biotherapeutics Inc. gained $0.04 in the last trading session, representing a 2.59% increase.
What is Calidi Biotherapeutics Inc. (CLDI) current market capitalization?
Calidi Biotherapeutics Inc. market cap is approximately 3.39 million.
What is Calidi Biotherapeutics Inc. (CLDI) Earnings Per Share (EPS)?
The trailing EPS is -$66.72, and the forward EPS is -$5.52.
What is Calidi Biotherapeutics Inc. (CLDI) EBITDA?
Calidi Biotherapeutics Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.12 million.
Does Calidi Biotherapeutics Inc. (CLDI) pay dividends?
No. Calidi Biotherapeutics Inc. does not pay a dividend.
What is Calidi Biotherapeutics Inc. (CLDI) beta (volatility) score?
Calidi Biotherapeutics Inc. has a beta of 1.333, suggesting it is more volatile than the market.
